Drug Trial Radar · NCT06887972
A Single-Arm Study Evaluating the Effectiveness and Safety of Suzetrigine (SUZ) for Acute Pain After Aesthetic or Reconstructive Surgeries
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
100
Actual
Start
Mar 21, 2025
Primary completion
Oct 24, 2025
Study completion Nov 7, 2025
Sponsor
- Lead sponsor
- Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
- Sponsor type
- Industry
- First posted
- Mar 21, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study evaluates the effectiveness, safety, and tolerability of SUZ as part of multimodal therapy (MMT) in treating acute postoperative pain.
Conditions
- Acute Pain
Interventions
SuzetrigineDrug
Tablets for oral administration.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Reporting Good, Very Good, or Excellent on a Patient Global Assessment (PGA) for Pain Control at the End of TreatmentTime frame: Day 14 or at Pain Resolution, whichever occurs first
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Atlanta Center for Medical Research
Atlanta, Georgia
Beth Israel Deaconess Medical Center - Surgery
Boston, Massachusetts
HD Research LLC | First Surgical Hospital
Bellaire, Texas
Memorial Hermann Village
Houston, Texas
JBR Clinical Research
Salt Lake City, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.